

Filipa Lynce

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/773180/publications.pdf>

Version: 2024-02-01

54
papers

2,080
citations

471509

17
h-index

254184

43
g-index

55
all docs

55
docs citations

55
times ranked

3114
citing authors

#	ARTICLE	IF	CITATIONS
1	Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2021, 384, 1529-1541.	27.0	601
2	Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, 1132.	7.1	285
3	Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types. <i>JCO Precision Oncology</i> , 2018, 2018, 1-13.	3.0	215
4	Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 1410.	7.1	161
5	Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 595-603.	2.5	106
6	TOPACIO/Keynote-162: Niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1011-1011.	1.6	63
7	CDK4/6 inhibitors in breast cancer therapy: Current practice and future opportunities. , 2018, 191, 65-73.		50
8	Genomic Disparities in Breast Cancer among Latinas. <i>Cancer Control</i> , 2016, 23, 359-372.	1.8	46
9	Management of Cardiovascular Disease in Women With Breast Cancer. <i>Circulation</i> , 2019, 139, 1110-1120.	1.6	45
10	How Far Do We Go With Genetic Evaluation? Gene, Panel, and Tumor Testing. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e72-e78.	3.8	40
11	Racial Disparities in the Molecular Landscape of Cancer. <i>Anticancer Research</i> , 2018, 38, 2235-2240.	1.1	32
12	SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function. <i>Oncologist</i> , 2017, 22, 518-525.	3.7	31
13	How Far Do We Go With Genetic Evaluation? Gene, Panel, and Tumor Testing. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 36, e72-e78.	3.8	28
14	First-in-human study of REGN3767 (R3767), a human LAG-3 monoclonal antibody (mAb), ± cemiplimab in patients (pts) with advanced malignancies.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2508-2508.	1.6	26
15	Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint. <i>Npj Breast Cancer</i> , 2018, 4, 26.	5.2	24
16	BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 345-355.	1.6	23
17	Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 265-275.	2.5	22
18	Cardiac function in BRCA1/2 mutation carriers with history of breast cancer treated with anthracyclines. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 285-293.	2.5	21

#	ARTICLE	IF	CITATIONS
19	Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 673-679.	2.3	20
20	Inhibiting Fatty Acid Synthase with Omeprazole to Improve Efficacy of Neoadjuvant Chemotherapy in Patients with Operable TNBC. <i>Clinical Cancer Research</i> , 2021, 27, 5810-5817.	7.0	19
21	Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 863-868.	2.5	18
22	Deleterious BRCA1/2 mutations in an urban population of Black women. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 201-209.	2.5	17
23	Role of Platinums in Triple-Negative Breast Cancer. <i>Current Oncology Reports</i> , 2021, 23, 50.	4.0	17
24	Pertuzumab for the Treatment of Breast Cancer. <i>Cancer Investigation</i> , 2014, 32, 430-438.	1.3	15
25	Video intervention increases participation of black breast cancer patients in therapeutic trials. <i>Npj Breast Cancer</i> , 2017, 3, 36.	5.2	15
26	Obesity in Adult Lymphoma Survivors. <i>Leukemia and Lymphoma</i> , 2012, 53, 569-574.	1.3	11
27	Prevalence of Phosphatidylinositol-3-Kinase (PI3K) Pathway Alterations and Co-alteration of Other Molecular Markers in Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1475.	2.8	11
28	Bone-Modifying Agents in Early-Stage and Advanced Breast Cancer. <i>Current Breast Cancer Reports</i> , 2018, 10, 241-250.	1.0	10
29	Lessons From Primary Cardiac Prevention Trials During Trastuzumab Therapy. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2869-2871.	2.8	9
30	Outcomes in patients (pts) aged ≥65 years in the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 1011-1011.	1.6	9
31	Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer. <i>Cancer</i> , 2021, 127, 3622-3630.	4.1	8
32	Characteristics and outcomes of breast cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase I clinical trials. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 35-41.	2.5	7
33	PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer. <i>Contemporary Clinical Trials Communications</i> , 2018, 10, 190-192.	1.1	7
34	Trends in the Use of Cardiac Imaging for Women with Newly Diagnosed Breast Cancer. <i>Journal of Cardiovascular Translational Research</i> , 2020, 13, 478-489.	2.4	7
35	SAFE-HEaRt: A pilot study assessing the cardiac safety of HER2 targeted therapy in patients with HER2 positive breast cancer and reduced left ventricular function.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1038-1038.	1.6	7
36	Profile of Margetuximab: Evidence to Date in the Targeted Treatment of Metastatic HER2-positive Breast Cancer. <i>OncoTargets and Therapy</i> , 2022, Volume 15, 471-478.	2.0	7

#	ARTICLE	IF	CITATIONS
37	Endocrine therapy initiation, discontinuation and adherence and breast imaging among 21-gene recurrence score assay-eligible women under age 65. <i>Breast Cancer Research</i> , 2017, 19, 45.	5.0	6
38	Initiation of Trastuzumab by Women Younger Than 64 Years for Adjuvant Treatment of Stage III Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 601-607.	4.9	6
39	Post-transfusion purpura in an African-American man due to human platelet antigen-5b alloantibody: a case report. <i>Journal of Medical Case Reports</i> , 2012, 6, 420.	0.8	5
40	First, Do no Harm. <i>Onkologie</i> , 2008, 31, 3-3.	0.8	4
41	Inhibiting fatty acid synthase in operable triple negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 584-584.	1.6	4
42	Actionable coalterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3132-3132.	1.6	4
43	Population-Based BRCA1/2 Testing in Ashkenazi Jews: Ready for Prime Time. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 809-812.	4.9	3
44	Left Ventricular Ejection Fraction Monitoring Adherence Rates. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 1094-1097.	5.3	3
45	A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 1145-1151.	2.3	3
46	Topical estrogen prescribing patterns for urogenital atrophy among women with breast cancer: results of a national provider survey. <i>Menopause</i> , 2019, 26, 714-719.	2.0	3
47	Tumor mutational load in gynecological and breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 44-44.	1.6	2
48	BRCA1/2 mutations and risk-reducing bilateral salpingo-oophorectomy among Latinas: The UPTAKE study. <i>Journal of Genetic Counseling</i> , 2021, 30, 383-393.	1.6	1
49	Trends in the use of adjuvant therapy for women with breast cancer under age 65.. <i>Journal of Clinical Oncology</i> , 2015, 33, e17541-e17541.	1.6	1
50	Abstract P1-18-13: Efficacy and safety of palbociclib plus endocrine therapy in Black and Hispanic patients with hormone receptor positive/human epidermal growth factor receptor 2-negative advanced breast cancer (HR+/HER2- ABC) participating in the PALOMA trials. <i>Cancer Research</i> , 2022, 82, P1-18-13-P1-18-13.	0.9	1
51	Avastin withdrawal symptoms. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 293-298.	1.8	0
52	Differences in Uptake of Risk Reduction Strategies Among Underserved Populations. <i>EBioMedicine</i> , 2015, 2, 1598-1599.	6.1	0
53	Differences in the molecular landscape of cancer between African American (AA) and Caucasian (CC) cancer patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6558-6558.	1.6	0
54	Abstract P5-14-08: Effectiveness of palbociclib plus letrozole vs letrozole in US Hispanic and African American patients with metastatic breast cancer: Flatiron database analysis. <i>Cancer Research</i> , 2022, 82, P5-14-08-P5-14-08.	0.9	0